search
Back to results

Evaluation of the MBio Combined Syphilis/HIV Point-of-Care Diagnostic Test (MBIO)

Primary Purpose

HIV, Syphilis

Status
Completed
Phase
Not Applicable
Locations
Kenya
Study Type
Interventional
Intervention
MBIO POC combined HIV syphilis test ( SnapEsi)
Sponsored by
PATH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for HIV focused on measuring HIV, Syphilis, Combination, POC, point-of-care, MBIO

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Pregnant
  • Attending her first routine ANC visit and willing to undergo tests for HIV/syphilis
  • Able and willing to legally consent for enrollment
  • Able to demonstrate-comprehension of study details as they are explained in the consent process by passing all the test questions of understanding. The subject is only allowed two attempts at passing the test of understanding.

Exclusion Criteria:

  • Unwilling to provide written informed consent.
  • Unable to legally consent (minor without guardian)
  • Opt out of HIV or syphilis test
  • Previously diagnosed with autoimmune disorder (lupus, Lyme disease), as determined by client recollection or clinical record.

Sites / Locations

  • Kisumu District Hospital
  • New Nyanza Provincial General Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

ANC clients

Arm Description

Outcomes

Primary Outcome Measures

Device sensitivity/specificity
Sensitivity & specificity of the MBIO device against HIV and syphilis reference tests

Secondary Outcome Measures

Percent agreement with clinical diagnosis
Percent agreement with HIV & syphilis rapid tests completed at clinic

Full Information

First Posted
January 23, 2012
Last Updated
October 27, 2014
Sponsor
PATH
Collaborators
Walter Reed Army Institute of Research (WRAIR), Kenya Medical Research Institute
search

1. Study Identification

Unique Protocol Identification Number
NCT01530672
Brief Title
Evaluation of the MBio Combined Syphilis/HIV Point-of-Care Diagnostic Test
Acronym
MBIO
Official Title
Evaluation of the MBio Combined Syphilis/HIV Point-of-Care Diagnostic Test
Study Type
Interventional

2. Study Status

Record Verification Date
October 2014
Overall Recruitment Status
Completed
Study Start Date
January 2012 (undefined)
Primary Completion Date
December 2012 (Actual)
Study Completion Date
September 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
PATH
Collaborators
Walter Reed Army Institute of Research (WRAIR), Kenya Medical Research Institute

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a diagnostic validation study for a combined Syphilis/HIV test made by MBio Diagnostics, Inc (MBio, Boulder, CO, USA). Although the MBio Syphilis/HIV diagnostic platform is designed for use at point of care (POC), it is made to provide similar performance as reference standards. Diagnosing HIV and syphilis accurately with a single POC test will save time for clinic health workers and technicians, reduce loss-to follow-up caused by lengthy delays for lab-based tests, and save costs by eliminating the need for multiple tests. For this study, the sensitivity and specificity of the MBio HIV/Syphilis Serology System point-of-care diagnostic test will be determined using reference tests performed under controlled laboratory conditions. For this, clients receiving routine care in the ANCs at the New Nyanza Provincial General Hospital (NNPGH) and Kisumu District Hospital (KDH) will be consented to provide blood for the proposed study. Study volunteers will receive HIV and syphilis rapid tests provided as part of routine care, and will donate an additional blood for evaluating the MBio test against the reference tests in a laboratory setting. This study is an investigational prototype, not for product registration. The results from this study will be used to inform product development of a second iteration of the MBio device design. At the time that the device is ready to be registered, it will undergo another field evaluation at which time it will be submitted to the appropriate regulatory body. Because the MBIO device is an HIV test, the device would be submitted to National AIDS & STI Control Program (NASCOP), which is the appropriate regulatory body for HIV tests in Kenya.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV, Syphilis
Keywords
HIV, Syphilis, Combination, POC, point-of-care, MBIO

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
2900 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ANC clients
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
MBIO POC combined HIV syphilis test ( SnapEsi)
Other Intervention Name(s)
MBIO, SnapEsi-beta HIV-1/Syphilis
Intervention Description
Venipuncture for routine ANC screening plus additional for device validation purposes.
Primary Outcome Measure Information:
Title
Device sensitivity/specificity
Description
Sensitivity & specificity of the MBIO device against HIV and syphilis reference tests
Time Frame
same-day
Secondary Outcome Measure Information:
Title
Percent agreement with clinical diagnosis
Description
Percent agreement with HIV & syphilis rapid tests completed at clinic
Time Frame
same-day

10. Eligibility

Sex
Female
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Pregnant Attending her first routine ANC visit and willing to undergo tests for HIV/syphilis Able and willing to legally consent for enrollment Able to demonstrate-comprehension of study details as they are explained in the consent process by passing all the test questions of understanding. The subject is only allowed two attempts at passing the test of understanding. Exclusion Criteria: Unwilling to provide written informed consent. Unable to legally consent (minor without guardian) Opt out of HIV or syphilis test Previously diagnosed with autoimmune disorder (lupus, Lyme disease), as determined by client recollection or clinical record.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Matthew Steele, Ph.D, M.P.H.
Organizational Affiliation
PATH
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
John Waitumbi, Ph.D, D.V.M.
Organizational Affiliation
Walter Reed Project
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Kathleen Tietje, PhD
Organizational Affiliation
PATH
Official's Role
Principal Investigator
Facility Information:
Facility Name
Kisumu District Hospital
City
Kisumu
State/Province
Nyanza
Country
Kenya
Facility Name
New Nyanza Provincial General Hospital
City
Kisumu
State/Province
Nyanza
Country
Kenya

12. IPD Sharing Statement

Links:
URL
http://www.mbiodx.com/technology/
Description
Related Info

Learn more about this trial

Evaluation of the MBio Combined Syphilis/HIV Point-of-Care Diagnostic Test

We'll reach out to this number within 24 hrs